Cryptosporidiosis - Pipeline Review, H2 2017

  • ID: 4426903
  • Report
  • 30 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • ioGenetics Inc
  • Novartis AG
  • Romark Laboratories LC
  • MORE
Cryptosporidiosis - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Cryptosporidiosis - Pipeline Review, H2 2017, provides an overview of the Cryptosporidiosis (Infectious Disease) pipeline landscape.

Cryptosporidiosis is an intestinal illness caused by a microscopic parasite called Cryptosporidium. Symptoms include watery diarrhea, dehydration, and lack of appetite, weight loss, fever, nausea and vomiting. Risk factors include contaminated water, animal handlers and parents of infected children.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Cryptosporidiosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Cryptosporidiosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cryptosporidiosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cryptosporidiosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Cryptosporidiosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cryptosporidiosis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Cryptosporidiosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cryptosporidiosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cryptosporidiosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cryptosporidiosis (Infectious Disease).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cryptosporidiosis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cryptosporidiosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • ioGenetics Inc
  • Novartis AG
  • Romark Laboratories LC
  • MORE
Introduction

Cryptosporidiosis - Overview

Cryptosporidiosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cryptosporidiosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cryptosporidiosis - Companies Involved in Therapeutics Development

AbbVie Inc

ioGenetics Inc

Novartis AG

Romark Laboratories LC

Cryptosporidiosis - Drug Profiles

DBAF-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EPLAJ-1317 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KDU-731 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-131 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RM-5038 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDPK1 for Protozoal Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cryptosporidiosis - Dormant Projects

Cryptosporidiosis - Discontinued Products

Cryptosporidiosis - Product Development Milestones

Featured News & Press Releases

May 31, 2017: Progress reported in global fight against diarrheal disease cryptosporidiosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Cryptosporidiosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Cryptosporidiosis - Pipeline by AbbVie Inc, H2 2017

Cryptosporidiosis - Pipeline by ioGenetics Inc, H2 2017

Cryptosporidiosis - Pipeline by Novartis AG, H2 2017

Cryptosporidiosis - Pipeline by Romark Laboratories LC, H2 2017

Cryptosporidiosis - Dormant Projects, H2 2017

Cryptosporidiosis - Discontinued Products, H2 2017

List of Figures

Number of Products under Development for Cryptosporidiosis, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • ioGenetics Inc
  • Novartis AG
  • Romark Laboratories LC
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll